Research Study

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
Principal Investigator 
Anthony Traboulsee

Overview

Body Locations and Systems 
Multiple Sclerosis
ClinicalTrials.gov# 
NCT03737851
Status 
Closed for Recruitment
Study Start/End 
Jul 9, 2019 to Aug 17, 2021
Locations 
UBC Hospital
Name/Title 
Research Coordinator, Guilaine Boyce
Phone 
604-827-1922
Email Address 
guilaine.boyce@ubc.ca
Purpose of Study 

 

The purpose of this study is to evaluate the safety and efficacy of elezanumab in subjects with relapsing Multiple Sclerosis (RMS).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.